The Latest
-
Getty Images
Drug discovery is speeding up. But clinical trials are buckling under their own weight.
A growing pipeline is colliding with tougher recruitment, more demanding protocols and trial operations struggling to keep pace — and AI alone can’t fix it.
-
Permission granted by Cytiva
Sponsored by CytivaBioprocessing observability: why real-time monitoring matters
What is bioprocess observability? See how real-time monitoring improves process control.
-
Pete Marovich via Getty Images
A CEO, an ex-CDC director and an ex-FDA commissioner walk into a biotech…
Dr. Robert Redfield and Dr. Stephen Hahn came aboard Turn Therapeutics this year to help the clinical-stage company develop a platform that could one day change how vaccines are delivered.
-
Getty Images
Pharma gift giving linked to writing more prescriptions — but less appropriate prescribing
The line between educating healthcare professionals and wooing them can still be fuzzy, which is impacting what doctors prescribe, according to a new analysis.
-
Getty Images
Biotech is booming — and startups are still dying
Despite an uptick in dealmaking and IPOs, a selective funding market and scientific setbacks are still pushing some biotechs to the brink.
-
Getty Images
Q&AAlzheimer’s trials need patients. Why are so many screened out?
A new report argues that more flexible eligibility criteria could widen pharma’s clinical trial pool without sacrificing safety.
-
Getty Images
FDA ‘reset’ continues with new plan for reviewing rare disease drugs
A revamped regulatory framework may give investors less of a “guessing game” as they weigh chances for drug approvals, one analyst said.
-
Getty Images
Hype vs. reality: What pharma’s hottest R&D bets have actually proved
New types of bispecifics, ADCs and CAR-Ts are still proving themselves in the clinic — pharma’s betting billions anyway.
-
Getty Images
Q&A // Biotech SpotlightA new startup takes aim at a suspected culprit in autoimmune disease
Ai3Bio recently emerged from stealth with preclinical programs aimed at what it believes could be a root cause of autoimmune conditions: diseased T cells.
-
Getty Images
Pharma’s manufacturing boom has a workforce problem
Drugmakers are pouring billions into U.S. production, but building enough plants won’t matter without enough skilled workers to run them.
-
Getty Images
Lilly is fighting a black market for its new obesity drug even before it launches
The large pharma’s promising new candidate retatrutide is still in the clinic. But Lilly is already fighting a web of illicit sellers for the drug online.
-
Permission granted by Merck & Co.
ProfileA day in the life of a Merck R&D chief
Dr. Eliav Barr pulls back the curtain on what it's like to manage Merck’s fast-growing pipeline.
-
Getty Images
HHS’ need for R&D speed; weird GLP-1 side effects
HHS is cranking up its efforts to accelerate drug development; more reports are emerging about off target effects of obesity drugs.
-
Getty Images
Pharma’s $500B patent problem will come in waves — not as a cliff
Merck is the most exposed to risk from generic competition in the short term, but AbbVie, Johnson & Johnson, Sanofi and others will also grapple with patent losses in the years to come.
-
Getty Images
5 key facts about the FDA expedited IND pilot program
The program, part of Operation TrialBlazer, aims to speed early research and help the U.S. bring trials back from overseas.
-
Getty Images
Top pharma industry conferences in 2027
Where pharma and biotech leaders will converge to network, share ideas and potentially strike deals.
-
Getty Images
The next frontier in obesity drugs: lasting weight loss
Alveus, Lilly, Viking and Amgen are testing maintenance strategies as durability becomes a bigger focus in obesity R&D.
-
Permission granted by Daiichi Sankyo
Q&AWill there be more to Daiichi’s story than DXd ADCs?
Dr. John Tsai grabbed the reins of global R&D this year with a clear mandate: extend Daiichi’s oncology momentum beyond its DXd franchise.
-
Getty Images
3 drug targets pharma is betting on next
Companies including GSK, Merck, Roche and Sanofi are pushing new approaches in cancer and inflammatory diseases.
-
Getty Images
Roche’s AI lab; Biohaven’s pivotal pause
Roche announced it's building autonomous AI-powered labs; how a clinical hold on an epilepsy trial could impact Biohaven
-
Getty Images
Are psychedelics as effective as trials suggest?
Patients often know when they’ve received a psychedelic, potentially distorting trial results. Researchers are testing new ways to make those studies more reliable.
-
Getty Images
An AI agent made a tiny drug R&D mistake. Then it kept going.
The error points to a big question for pharma as AI gains autonomy and high-profile failures sharpen safety concerns: What happens when a wrong answer becomes the basis for the next decision?
-
Getty Images
Beam sues 2 biotechs, alleging theft of base editing trade secrets
Beam claimed a former scientist stole confidential information and quietly spun up a rival rare disease treatment at YolTech Therapeutics. Serapha Bio, which licensed that therapy, denies the charges.
-
Getty Images
Epilepsy R&D is breaking out of its old playbook
Genetic medicines and more selective small molecules are finally pushing the field toward new mechanisms — and potentially disease-modifying treatments.
-
Permission granted by Bavarian Nordic
What Bavarian Nordic’s next CEO is up against
The Danish biotech sharpened its global vaccine ambitions by tapping Tarja Stenvall, a Big Pharma vet, to take the helm.
-
Getty Images
Nimbus used AI to help develop Takeda’s $4B psoriasis bet. Here’s where it’s taking the tech next
Nimbus Therapeutics’ head of R&D dishes on what’s next in AI-enabled drug discovery, years after Takeda completed its zasocitinib acquisition.
